Study Finds THC and CBD Combination Reduces Inflammation in Immune Cells From Multiple Sclerosis Patients

A combination of THC and cannabidiol (CBD) significantly suppressed inflammatory signaling in immune cells taken from people with multiple sclerosis (MS), according to a study accepted November 2 by Frontiers in Immunology.

Researchers from Trinity College Dublin, Beaumont Hospital and other institutions in Ireland examined how the two cannabinoids, individually and together, affected a key inflammatory mechanism associated with multiple sclerosis.

The study involved blood-derived immune cells collected from 61 participants, including 31 people with multiple sclerosis and 30 healthy controls. Researchers tested CBD, THC and a combination containing equal concentrations of both compounds, designed to resemble the cannabinoid formulation used in Sativex, a prescription medication used to manage symptoms of multiple sclerosis.

The experiments focused on the NLRP3 inflammasome, a component of the immune system involved in triggering inflammatory responses. Excessive activation of this pathway has been implicated in the development and progression of multiple sclerosis.

Researchers measured changes in two inflammatory proteins, interleukin-1 beta (IL-1β) and interleukin-18 (IL-18), after exposing immune cells to substances that activate the NLRP3 pathway.

In cells obtained from healthy participants, CBD, THC and their combination each reduced inflammatory signaling in a dose-dependent manner when administered before the initial inflammatory stimulus.

However, results differed considerably in cells collected from multiple sclerosis patients.

Among these cells, consistent suppression of inflammatory signaling occurred only when CBD and THC were administered together at concentrations of 10 micromolar each before the initial activation process.

CBD alone, despite demonstrating anti-inflammatory activity in cells from healthy participants, generally lost that effectiveness in cells obtained from people with multiple sclerosis.

The timing of cannabinoid administration also proved important. When researchers administered the compounds immediately before the second stage of inflammasome activation, none of the cannabinoid treatments produced anti-inflammatory effects in cells from multiple sclerosis patients.

The findings suggest that the interaction between THC and CBD may be particularly important when targeting inflammatory mechanisms associated with the disease.

Researchers concluded that CBD’s ability to inhibit NLRP3 signaling was “largely lost in immune cells from pwMS unless it is combined with THC and administered prior to priming.”

The findings provide additional insight into the biological activity of cannabinoid combinations used in multiple sclerosis treatment, identifying a specific inflammatory pathway that responds differently to combined cannabinoids than to either compound administered independently.